India Glycols Intrinsic Value
INDIAGLYCO • Consumer Goods
Current Stock Price
₹895.65
Primary Intrinsic Value
₹1051.00
Market Cap
₹2777 Cr
+17.3%
Upside
Median Value
₹1051.00
Value Range
₹269 - ₹1819
Assessment
Trading Below Median Value
Safety Margin
14.8%
INDIAGLYCO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1051.00 | ₹840.80 - ₹1261.20 | +17.3% | EPS: ₹42.04, Sector P/E: 25x |
| Book Value Method | asset | ₹1819.35 | ₹1637.41 - ₹2001.29 | +103.1% | Book Value/Share: ₹727.74, P/B: 2.5x |
| Revenue Multiple Method | revenue | ₹1791.30 | ₹1612.17 - ₹1970.43 | +100.0% | Revenue/Share: ₹1427.10, P/S: 1.5x |
| EBITDA Multiple Method | earnings | ₹1791.30 | ₹1612.17 - ₹1970.43 | +100.0% | EBITDA: ₹684.00Cr, EV/EBITDA: 12x |
| Simple DCF (5Y) | dcf | ₹1586.18 | ₹1268.94 - ₹1903.42 | +77.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹269.06 | ₹242.15 - ₹295.97 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹779.42 | ₹701.48 - ₹857.36 | -13.0% | Revenue Growth: 6.0%, Adj P/E: 18.5x |
| ROE Based Valuation | profitability | ₹1006.45 | ₹905.81 - ₹1107.10 | +12.4% | ROE: 11.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹829.68 | ₹746.71 - ₹912.65 | -7.4% | EPS: ₹42.04, BVPS: ₹727.74 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
INDIAGLYCO Intrinsic Value Analysis
What is the intrinsic value of INDIAGLYCO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of India Glycols (INDIAGLYCO) is ₹1051.00 (median value). With the current market price of ₹895.65, this represents a +17.3% variance from our estimated fair value.
The valuation range spans from ₹269.06 to ₹1819.35, indicating ₹269.06 - ₹1819.35.
Is INDIAGLYCO undervalued or overvalued?
Based on our multi-method analysis, India Glycols (INDIAGLYCO) appears to be trading below median value by approximately 17.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.14 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 11.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.72x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for India Glycols
Additional stock information and data for INDIAGLYCO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹362 Cr | ₹-6 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹439 Cr | ₹187 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹326 Cr | ₹161 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹116 Cr | ₹116 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹137 Cr | ₹63 Cr | Positive Free Cash Flow | 7/10 |